HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 60 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,737,795 | -59.5% | 205,609 | -56.5% | 0.01% | -61.5% |
| Q2 2023 | $16,646,272 | -17.0% | 473,040 | -23.1% | 0.01% | -18.8% |
| Q1 2023 | $20,064,839 | -44.3% | 614,841 | -5.9% | 0.02% | -44.8% |
| Q4 2022 | $35,995,838 | +13.8% | 653,282 | -8.5% | 0.03% | +3.6% |
| Q3 2022 | $31,617,000 | -1.2% | 713,865 | +8.8% | 0.03% | +7.7% |
| Q2 2022 | $31,990,000 | +16.1% | 655,946 | +15.8% | 0.03% | +36.8% |
| Q1 2022 | $27,551,000 | +35.8% | 566,308 | +19.0% | 0.02% | +46.2% |
| Q4 2021 | $20,289,000 | +180.4% | 475,824 | +152.0% | 0.01% | +160.0% |
| Q3 2021 | $7,237,000 | +35.8% | 188,811 | +0.0% | 0.01% | +25.0% |
| Q2 2021 | $5,328,000 | +6.7% | 188,741 | +24.9% | 0.00% | 0.0% |
| Q1 2021 | $4,992,000 | +16.5% | 151,091 | +27.5% | 0.00% | +33.3% |
| Q4 2020 | $4,286,000 | +24.9% | 118,549 | +17.1% | 0.00% | 0.0% |
| Q3 2020 | $3,431,000 | – | 101,212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |